AccessibilityHelpAbout Us
Lakefront Biotherapeutics logo

Lakefront Biotherapeutics(NASDAQ) LKFT

Market Cap$1.87BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2008)+264%
5 Year-49%
1 Year-14%
1 Month-3%
Premium Feature
Moneyball Superscore
42/100
$29.62
+3.75%
+1.07Today
After hours$29.61-$0.01 (-0.03%)
Lakefront Biotherapeutics last closing stock price
MetricPriceDate
Last closeUSD 28.552026-09-18
Lakefront Biotherapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+6.49%USD 26.812026-09-11
1 month-2.76%USD 29.362026-08-19
3 month+0.88%USD 28.302026-06-18
Year to date-12.69%USD 32.702025-12-31
1 year-14.11%USD 33.242025-09-18
3 year-20.07%USD 35.722023-09-19
5 year-48.69%USD 55.642021-09-17
Since inception+263.69%USD 7.852008-07-07

Lakefront Biotherapeutics Financials at a Glance

Market Cap

$1.87BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

€990.58M

Net Income (TTM)

€596.64M

EPS (TTM)

$10.52

P/E Ratio

2.71

Dividend

$0.00

Beta (Volatility)

0.60 (Low)

Price

$29.62

Volume

208,121.662

Open

$28.67

Previous Close

$29.59

Daily Range

$28.60 - $29.73

52-Week Range

$25.68 - $37.78

Estimated Earnings Date

Nov 12, 2026

LKFT News

GettyImages-944545988

Why Galapagos Trounced the Market Today

Eric VolkmanJan 27, 2022
investor-looking-at-charts-getty

Here's Why Galapagos Stock Is Falling Today

Cory RenauerJul 15, 2021
life-science-professionals

Is Galapagos Stock a Bad-News Buy Right Now?

Cory RenauerFeb 23, 2021
Thumb down

Why Galapagos Stock Is Crashing Today

Keith SpeightsAug 19, 2020
1-2-3-going-up

3 Biotech Stocks With Big Incoming Catalysts

Cory RenauerJul 25, 2020
GettyImages-506712062

Better Buy: Vertex Pharmaceuticals vs. Galapagos

Zhiyuan SunJul 2, 2020
confused-businessman-getty

Galapagos and Gilead Sciences Post Successful Yet Disappointing Filgotinib Results

Cory RenauerMay 21, 2020
GettyImages-187921657

Is Galapagos Stock a Buy?

David HaenApr 12, 2020
Page 1

LKFT: Motley Fool Moneyball Superscore

42

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Lakefront Biotherapeutics

Lakefront Biotherapeutics N.V. is a biotechnology company focused on transforming patient outcomes through scientific innovation. The company is dedicated to developing a pipeline of medicines for serious diseases, particularly in oncology and immunology.

Products and Services
  • Clinical-stage portfolio targeting autoimmune diseases
  • Potential first-in-class treatments in oncology
  • Innovative therapies addressing unmet medical needs
Growth Outlook
  • Strong focus on expanding therapeutic areas in oncology and immunology
  • Recent partnerships enhancing research capabilities and market reach
  • Pipeline advancements expected to drive future revenue growth
Financial Highlights
  • Recent quarterly revenue of 12.12 million, showing significant growth
  • Trailing twelve months (TTM) net income margin of 60.23%
  • Current ratio of 32.82 indicates strong liquidity position
Lakefront Biotherapeutics N.V. is positioned in the biotechnology sector, focusing on innovative solutions for serious health conditions. The company’s commitment to research and development is evident in its clinical-stage portfolio, which aims to deliver first-in-class treatments. Recent financial performance indicates a robust growth trajectory, with a notable increase in quarterly revenue and a strong net income margin. The company's liquidity is also impressive, suggesting a solid foundation for future investments and operational needs. As Lakefront Biotherapeutics continues to advance its pipeline, it remains a compelling entity within the biotechnology landscape.
AI Generated • Sep 18, 2026

Industry

Biotechnology

Sector

Health Care

Employees

196

CEO

Henry O. Gosebruch, CPA

Website

www.galapagos.com

Headquarters

Mechelen, 2800, BE

LKFT Financials

Key Financial Metrics (TTM)

Gross Margin

94.88%

Operating Margin

61.57%

Net Income Margin

60.23%

Return on Equity

19.58%

Return on Capital

15.46%

Return on Assets

17.81%

Earnings Yield

36.90%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.87BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

65.66M

Volume

208.12K

Avg. Volume

229.31K

Financials (TTM)

Gross Profit

€939.84M

Operating Income

€609.93M

EBITDA

€541.60M

Operating Cash Flow

-€192.82M

Capital Expenditure

-€4.58M

Free Cash Flow

-€197.40M

Cash & ST Invst.

€2.24B

Total Debt

€6.36M

Lakefront Biotherapeutics Performance Analysis

Lakefront Biotherapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31EUR 253,546,503-55.8%
20232023-12-31EUR 259,169,3572.2%
20242024-12-31EUR 298,166,97515.0%
20252025-12-31EUR 1,255,258,568321.0%
Lakefront Biotherapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-309.0%
Q42025-12-311165.9%
Q12026-03-31-99.3%
Q22026-06-3087.0%
Lakefront Biotherapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31EUR -3.4954.1%
20232023-12-31EUR 3.47N/A
20242024-12-31EUR 1.22-65.0%
20252025-12-31EUR 5.50351.9%
Lakefront Biotherapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-91.9%
Q42025-12-31486.6%
Q12026-03-31-98.1%
Q22026-06-30-87.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

€12.12M

-81.4%

Gross Profit

-€22.52M

-137.2%

Gross Margin

-1.86%

N/A

Market Cap

$1.87BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$4.15M

N/A

Employees

452

N/A

Net Income

€2.11M

+102.0%

EBITDA

-€35.27M

+65.1%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

€2.24B

-27.6%

Total Debt

€6.36M

-24.7%

Accounts Receivable

€56.27M

-35.9%

Inventory

€0.00

-100.0%

Long Term Debt

€4.77M

-21.1%

Short Term Debt

€1.59M

-33.6%

Return on Assets

17.81%

N/A

Return on Invested Capital

18.60%

N/A

Free Cash Flow

€0.00

+100.0%

Operating Cash Flow

€0.00

+100.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,763.63+0.01%
^DJIDJI
$52,032.71+0.01%
^IXICNASDAQ
$27,092.05+0.02%
BTCBitcoin
$85,915.00+0.06%

Trending Stocks

Symbol / CompanyPricePrice Chg
WBDWarner Bros. Discovery
$30.80+10.79%
GRMLGreenland Mines
$9.42+230.53%
INTCIntel
$121.78+12.14%
NVDANvidia
$227.38+2.30%

Questions About LKFT

What is the current price of Lakefront Biotherapeutics?

Lakefront Biotherapeutics is trading at $29.59 per share.

What is the 52-week range for Lakefront Biotherapeutics?

Over the past 52 weeks, Lakefront Biotherapeutics has traded between $25.68 and $37.78.

How much debt does Lakefront Biotherapeutics have?

As of the most recent reporting period, Lakefront Biotherapeutics reported total debt of €7.27M.

How much cash does Lakefront Biotherapeutics have on hand?

Lakefront Biotherapeutics reported €155.43M in cash and cash equivalents in its most recent financial results.

What is Lakefront Biotherapeutics’s dividend yield?

Lakefront Biotherapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services